



Tanvex Settles Patent Dispute with Amgen

December 17, 2019

Tanvex announced that the company has reached an agreement with Amgen to settle the patent lawsuit related to Amgen's US patent 9,856,287. All terms of the settlement agreement are confidential. The legal action, which is pending in the U.S. District Court for the Southern District of California, will be dismissed as a result of the settlement.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.